MNPR
Monopar Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.56
−0.84%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.86
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.62
- EPS estimate
- -$0.64
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $126
- PT range
- $119 – $133
- Analysts
- 4
3 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026